Citations

Clear

2429 citation(s) found for "Shah, SS".

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)
Varma, Gaurav , Rosenberg, Maya, Agbadiba, Erica C., Yeung, Austin H., Baek, Grace , Besien, Herman van, Baron, Kelsey, Subramanian, Meghana K., Prischak, Sara, Lukowski, Joe D., D’Angelo, Christopher R. , Svoboda, Jakub , Yamshon, Samuel , Advani, Ranjana H. , Advani, Ranjana H , Yeung, Austin H., Falade, Ayo , Watkins, Marcus P. , Subramanian, Meghana K., Rhodes, Joanna , Shah, Harsh , Gopal, Ajay K. , Bartlett, Nancy L. , Merryman, Reid W. , Ahmed, Sairah , Diefenbach, Catherine

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4425-4425

10.1182/blood-2024-197923 Get It

Introduction Emerging evidence suggests that responses to CPI in Hodgkin lymphoma (HL) may be adversely affected by the reductions in microbiome diversity associated with concomitant antibiotic (abx) exposure. Given the increasingly key role that CPI-based regimens (CPI+) appear to have on improving post-ASCT outcomes, we evaluated the potential impact of abx exposure on CPI+ efficacy and post-ASCT outcomes in RRHL patients treated with CPI+ prior to ASCT. Methods This retrospective study of RRHL patients at 11 US academic centers included patients ≥18 who received CPI+ between 1/2012-12/2022. Patient/disease characteristics, treatment histories, outcomes, and abx exposure (2 weeks prior to and 30 days after CPI+) were collected by participating sites and analyzed centrally. Primary and key secondary objectives were overall response rate (ORR) to CPI+ by Lugano criteria, and PFS/overall survival (OS) by abx exposure. PFS/OS were estimated by Kaplan-Meier and compared by log-rank tests. Univariate and multivariate regression models evaluated the impact of abx exposure on ORR/complete response rate (CR)/PFS/OS. Results 237 patients with median follow-up of 3.20 and 2.73 years from CPI+ initiation and ASCT, respectively, were evaluated. At diagnosis: median age 30.6 (range 7.8 - 71.7) years, female (53.6%), nodular sclerosing (75.1%), and stages I-IIB/bulky and III/IV (73.4%). 1L regimens were ABVD/ABVD-like (75.5%), brentuximab vedotin (BV)+AVD (15.2%), and other (9.3%). 65.8% received 6 cycles of chemotherapy, and 10.5% received 1L radiation. End of 1L responses were CR (39.7%), partial response (PR; 13.1%), refractory disease (37.6%), and unknown (8.0%). Median time to first relapse from diagnosis was 0.95 (range 0.15 - 22.2) years. All patients underwent ASCT after 1 (58.2%), 2 (22.8%), or 3+ (19.0%) lines of salvage. CPI+ was given as 1st (65.8%), 2nd (21.5%), or 3rd+ (12.5%) salvage therapy. CPI+ included BV-nivolumab (44.3%) + ipilimumab (7.2%), pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin (P-GVD; 24.5%), and CPI-monotherapy (20.2%). ORR to CPI+ was 88.0% (CR 68.4%) in all lines; as 1st salvage ORR was 91.7% (CR 76.3%). 75.1% of patients underwent ASCT in CR (PR 19.4%) increasing to 91.1% CR after ASCT. At 3-years, PFS was 88.0% (95% CI: 83.5% - 92.8%) and OS was 94.8% (95% CI: 91.3% - 98.3%) for the full cohort. Overall, 46.8% patients were abx exposed during CPI+, 22.8% fluoroquinolone/beta-lactams (BL) prophylaxis (ppx) and 38.8% abx [BL 29.5%, carbapenems (CB) 12.2%, vancomycin (VM) 19.8%, anti-pseudomonas (PA) 24.9%, anti-MRSA (SA) 22.4%, anti-anaerobe (AN) 16.5%] for suspected/documented infection. Use of ppx, BL, CB, VM, PA, SA were significantly higher with CP1+ as 2nd+ vs 1st salvage. At 3-years, PFS (87.0% vs 88.4%, p=0.91) and OS (92.5% vs 95.8%, p=0.47) were similar for abx exposed vs naïve patients, respectively. On univariate analysis, line of salvage and CPI+ regimen (Cytotoxic vs Monotherapy) were associated with ORR/CR, while overall abx exposure was not associated with inferior ORR (OR 0.62; p=0.24), CR (OR 0.85, p=0.56), PFS (HR 0.95, p=0.91), or OS (HR 1.58, p=0.47). When adjusted for line of salvage and CPI+ regimen, exposure to BL, CB, VM, PS, SA, or AN, abx indication (ppx vs treatment), duration of abx exposure (<7 vs ≥7 days) by class were all not associated with ORR/CR or PFS/OS. Conclusion In this large cohort abx exposure does not appear to adversely affect ORR/CR to CPI+ or PFS/OS following ASCT, when adjusted for line of CPI+ salvage and CPI+ regimen. Our findings may be related the high proportion of patients (79.8%) receiving CPI-combinations compared to CPI monotherapy (20.2%), whereas in previous series all patients received CPI without cytotoxic agents. This observation could be related to intrinsic antimicrobial activities of some cytotoxic agents (e.g. gemcitabine and doxorubicin) that may overshadow impact from concomitant abx exposure. Alternatively, the lack of effect could be related to the inherent fitness of patients with RRHL who undergo ASCT, compared to those treated with CPI+ following ASCT or those with solid tumors receiving where abx exposure may indicate an overall sicker/higher-risk population. Overall, our findings demonstrate that combination of CPI with BV or chemotherapy may overcome any adverse impact of abx on the efficacy of CPI+ prior to ASCT.
Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
Baek, Grace , Varma, Gaurav , Yamshon, Samuel , Besien, Herman van, Baron, Kelsey, Svoboda, Jakub , Prischak, Sara, D’Angelo, Christopher R. , Lukowski, Joe D., Advani, Ranjana H. , Yeung, Austin H., Rosenberg, Maya, Lynch, Ryan C. , Raghunathan, Vikram , Smith, Stephen D. , Ujjani, Chaitra S. , Advani, Ranjana H , Bartlett, Nancy L. , Watkins, Marcus P. , Shah, Harsh , Merryman, Reid W. , Falade, Ayo , Yeung, Austin H., Voutsinas, Jenna M. , Di, Mengyang , Poh, Christina , Raghunathan, Vikram M. , Shadman, Mazyar , Till, Brian G. , Diefenbach, Catherine , Gopal, Ajay K.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4431-4431

10.1182/blood-2024-200719 Get It

Introduction: Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) has become a commonly employed regimen for the treatment of relapsed or refractory classical Hodgkin lymphoma (CHL), often preceding autologous stem cell transplant in patients with good response. The utilization of P-GVD is based on a 38-evaluable patient prospective trial (Moskowitz et al. JCO 2021). There remains minimal data regarding the efficacy of this regimen in a larger, real-world cohort. Methods:Patients with CHL who received P-GVD at 9 United States centers were retrospectively evaluated to estimate efficacy and safety, with a focus on the second line use of this regimen. Demographic and clinical data were extracted from medical records. Responses reflected Lugano criteria per local investigator assessment. Study objectives were overall response rates (ORR), complete response rates (CRR), progression free survival (PFS), overall survival (OS), and safety. PFS and OS were estimated by Kaplan-Meier. Results: Patients and Treatment: We identified 65 CHL patients who received P-GVD between July 2019 and June 2024, including 43 who were treated in the second line. Enrolled patients included a median age of 31 years (range 17-69 years), 36.9% (24) females, 75.4% (49) nodular sclerosing subtype, and 60% (39) stage III-IV at diagnosis. Patients included 64.6% (42) White and non-Hispanic, 15.4% (10) Hispanic or White and Hispanic, 10.8% (7) Black, 3.1% (2) Asian/Pacific Islander, 3.1% (2) other, and 3.1% (2) unknown. The median number of prior regimens was 1 (range 0-12); these included 3.1% (2) who had prior checkpoint inhibitor (CPI), 50.8% (33) who had prior brentuximab vedotin (BV), and 3.1% (2) who had prior transplant. Patients with primary refractory disease [no initial complete response (CR)] comprised 58.5% (38), and 35.4% (23) had relapse within 1 year of completing initial therapy. The median number of cycles received was 3 (range 1-5). Treatment in a community practice setting was noted for 21.5% (14) patients. Efficacy: At a median follow up of 17.7 months, ORR and CRR after P-GVD were 95% (62/65) and 74% (48/65), respectively. This increased to 95% ORR and 81% CRR when limited to 43 patients who were treated 2nd line. Responses by line included: 1st [n=1; 100% ORR and CRR]; 3rd [n=15; 100% ORR, 73.3% CRR], 4th [n=3; 100% ORR, 33.3% CRR], 5th [n=2; 100% ORR, 0% CRR], and 13th [n=1; SD]. CRR in BV- and CPI-exposed patients were 60.6% and 50%, respectively. Ninety one percent (39) of 2nd line treated patients proceeded to autologous transplant, as well as all 3 patients > age 60. Among 41 response-evaluable second-line patients, CR was achieved in 94% (30/32) who received 2 or 3 cycles of P-GVD, and 56% (5/9) who received 4 cycles of P-GVD. For the entire cohort at 12 and 24 months after starting P-GVD, PFS was 95% (95% CI: 89-100%), 91% (95% CI: 83-100%) and OS was 98% (95% CI: 94-100%), 94% (95% CI: 86-100%), respectively. Ninety five percent (41) of 2nd line transplanted patients remain alive and in remission at a median of 18.5 months (range 3.5-38.7 months). In the primary refractory subset, PFS and OS at 24 months were 91% and 97%, respectively. For the cohort with 2 or more prior lines of therapy, PFS and OS at 24 months were 91% and 94%, respectively. Safety: Immune-related adverse events (IRAEs) were reported in 20% (13) of patients, of which grade 3 IRAEs per NCCN criteria version 1.2024 comprised 38.5%; all others were grades 1-2. Non-IRAE grade 3-4 toxicities per CTCAE version 5.0 were reported in 22% (14) patients. Of 29 patients evaluable for treatment-related interruptions, 7% (2) had therapy discontinued, and 34% (10) had holds, dose reductions, and/or delays. No deaths were attributed to P-GVD treatment. Conclusions:This retrospective study confirms the utility of P-GVD in treating relapsed/refractory CHL in a real-world population. Though fewer CRs and higher rates of grade 3 adverse events were observed, the vast majority of patients were able to proceed to transplant, and outcomes to date are highly encouraging.
Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms
Ruan, Gordon , Davidge‐Pitts, Caroline , Gruber, Lucinda , Sartori‐Valinotti, Julio C. , Jiang, Liuyan , Ahmed, Asra, Abeykoon, Jithma P. , Yi, Dongni , Go, Ronald S. , Bennani, N. Nora , Shah, Meera , Rech, Karen L. , Ravindran, Aishwarya , Ryu, Jay H. , Vassallo, Robert , Koster, Matthew J. , Tobin, W. Oliver , Hilal, Talal , Moustafa, Muhamad Alhaj , Goyal, Gaurav

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3181-3181

10.1182/blood-2024-193841 Get It

Background: Erdheim-Chester disease (ECD) manifests as multi-organ infiltration of clonal histiocytes with mutations primarily in the mitogen-activated protein kinase (MAPK) pathway. The revised classification of histiocytosis (2016) categorizes ECD with typical bilateral, symmetric osteosclerosis of the lower extremity long bones as classical (C) and as non-classical (NC) if otherwise. The clinical and biological significance of this classification is unclear. This study compared the clinical and genotypic findings of the 2 subtypes within a large cohort of ECD patients. Methods: We included patients seen at our institution since 1990 meeting the following criteria: A) had an ECD diagnosis based on the revised criteria by Haroche J, et al. (Blood 2020;135:1311-1318); B) completed whole-body imaging studies including long bones of the legs. Classification as C-ECD required symmetric osteosclerosis of the distal femur and/or proximal tibia/fibula. Results: A total of 145 patients were enrolled, comprising a male-to-female ratio of 2:1 (66.2% male). C-ECD was diagnosed in 77.2% of cases, and NC-ECD in 22.8%. The median age at diagnosis was similar with 58.5 years (range, 18-82) in C-ECD and 55 years (range, 20-81) in NC-ECD, (p=0.65). The most frequently affected systems included skeletal (81.4%), renal (60.0%), vascular (45.5%), cardiac (40.0%), central nervous (38.6%), sinus (37.2%), pulmonary (36.6%), and adrenal (32.4%). The numbers of organs involved were significantly higher in C-ECD compared to NC-ECD (median 5 vs 3, p<0.01). Higher rates of skeletal (100% vs. 18.2%, p<0.01), adrenal gland (37.5% vs. 15.2%, p=0.02), and sinus (44.6% vs. 12.1%, p<0.01) involvement were observed in C-ECD. Arginine vasopressin deficiency (AVP-D) was exclusively observed in C-ECD (20.7% vs. 0%, p<0.01). NC-ECD had a higher rate of cardiac involvement (69.7% vs. 31.3%, p<0.01). No significant differences were found in other systems. The overall median time between onset of the first symptoms/signs to diagnosis was 15 months with no significant difference between C-ECD and NC-ECD (17.5 vs. 12 months, p=0.18). The median time to diagnosis of ECD in patients with AVP-D was 38.5 months, compared to 12 months without AVP-D (p=0.09). Genetic testing was conducted in 86.2% of patients and B-Raf proto-oncogene (BRAF) alterations were identified in 59.2% of the tested cases. BRAFV600E was more prevalent in C-ECD (61.3% vs. 21.9%, p<0.01), whereas non-V600 mutations were more commonly found in NC-ECD (12.5% vs. 1.1%, p<0.01). There was no significant difference in the frequency of BRAF fusions. NC-ECD patients exhibited a higher rate of MAP2K1 mutations (25.0% vs. 5.4%, p<0.01). Other frequently mutated genes included KRAS (4.0%), NRAS (2.4%), and CSF1R (2.4%), although no significant difference was observed in their frequency between C-ECD and NC-ECD. Testicular involvement appeared to be more common in patients with MAP2K1 mutations (23.1% vs. 8%, p=0.08). Two patients with pathogenic CSF1R mutations both had central nervous system (CNS) involvement. Among C-ECD patients, BRAFV600E conferred a higher rate of CNS involvement (50.9% vs. 25%, p=0.01). No significant difference was observed in NC-ECD patients (71.4% vs 36%, p=0.09). Among NC-ECD cases, MAP2K1 mutations conferred a reduced risk of cardiac involvement (37.5% vs. 79.2%, p=0.03) and no such difference was observed in patients with C-ECD (40% vs 34.1%, p=0.79). The median numbers of organs involved in patients with BRAF, MAP2K1, and KRAS/NRAS mutations were 5, 3, and 3, respectively, with no significant difference. Conclusions: C-ECD affects more organs and more frequently involves bones, adrenal glands, and sinuses. AVP-D was exclusively observed in C-ECD. Conversely, NC-ECD showed a higher prevalence of cardiac involvement. BRAFV600E was more commonly identified in C-ECD, whereas non-V600 mutations and MAP2K1 mutations were more prevalent in NC-ECD. Among C-ECD patients, BRAFV600E was correlated with a greater likelihood of CNS involvement. Conversely, NC-ECD patients with MAP2K1 mutations had a reduced risk of cardiac involvement. This study highlights the distinct clinical and molecular features of C-ECD and NC-ECD, underscoring the importance of subclassifying ECD into classical and non-classical forms. Further studies are needed to explore differences in the clinical outcomes between the 2 forms.
A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations
Yacout, Mahmoud, Katamesh, Bahga , Jabban, Yazan, He, Rong , Foran, James M. , Yi, Cecilia Y. Arana , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Al‐Kali, Aref , Greipp, Patricia T. , Jevremović, Dragan , Yi, Cecilia Arana , Saliba, Antoine N. , Shah, Meera , Alkhateeb, Hassan B.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 2667-2667

10.1182/blood-2024-208957 Get It

Background: Clonal cytopenia of undetermined significance (CCUS), a precursor of myeloid neoplasms (MN), is characterized by one or more persistent cytopenias, and acquired mutations in myeloid malignancy-associated genes. ZRSR2, located at Xp22.2, is one of the MN-associated genes and a member of the spliceosome family of genes. Aim: Describe the clinical characteristics, pattern of progression, and genetics of ZRSR2 mutation (ZRSR2m)-harboring CCUS patients. Methods: Next-generation sequencing (NGS) was performed for 9320 patients between 2016-2023 at Mayo Clinic. After obtaining IRB approval, clinical characteristics and results of bone marrow morphology, cytogenetics, and molecular studies were abstracted. Overall Survival (OS) was calculated using Kaplan-Meier, from the date of NGS until death or last follow-up. The ZRSR2m MN control cohort included 125 patients with myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), and MDS/MPN overlap. BlueSky Statistics V10.3.1 was used for statistical analysis. Results: ZRSR2m was detected in 39 CCUS patients, all of whom were males. Concurrent hematological neoplasms were identified in 8 patients (21%). Five (13%) had plasma cell proliferative disorders including 3 multiple myeloma, 1 MGUS, and 1 AL amyloidosis. There were also 2 patients with chronic lymphocytic leukemia and 1 with VEXAS syndrome. Prior chemotherapy, with or without radiotherapy, was given to 4 patients (10.3%), whereas 13 patients (33%) had received previous immunotherapy. Abnormal cytogenetics were detected in 11 patients (29%), with the most common abnormality being +8 (n=5, 13%). In 23 patients (59%), an absolute monocyte count of ≥0.5 x 10^9/L was documented which could be classified as clonal cytopenia with monocytosis of unknown significance (CCMUS). ZRSR2 median gender-corrected VAF among CCUS patients was 32% (range, 1-45). Isolated ZRSR2m was found in 6 patients (15%), and 1 (3%) had multiple ZRSR2m. The median number of co-mutations was 1 (range, 0-3). Sequential NGS, available in 13 patients, showed that 1 patient developed 3 ZRSR2 mutations and 2 ZRSR2 VUS. TET2 was the most common co-mutation (n=25, 64%). Additionally, TET2 was an isolated co-mutation in 18 patients (46%). ASXL1 co-mutation was the second most common (n=8, 20.5%), while other less common co-mutations were IDH1, IDH2, SRSF2, SF3B1, TP53, GATA2, and KDM6A. Pre-ZF1 was the most commonly mutated region in ZRSR2 mutations (n=23, 59%). With a median follow-up of 32 months, 9 (23%) of the ZRSR2m CCUS patients progressed to MNs, none progressed to AML. Five (55.6%) progressed to MDS, 4 were subclassified as low blast (LB) and 1 as increased blast-1 (IB1). Four (44.4%) progressed to MDS/MPN overlap syndrome, with 3 subclassified as chronic myelomonocytic leukemia (CMML). None of the patients with isolated ZRSR2m progressed to MDS or CMML. None of the patients who received prior immunotherapy progressed to MDS. Thirty-six (92.3%) patients had high-risk CCUS (Malcovati et al, Blood 2017) while 3 had intermediate risk with no low-risk patients. None of the intermediate-risk patients progressed to MDS, while 5 patients of the high-risk (13.9%) progressed to MDS (p=1). Twelve (31%) patients died, and the median overall survival (mOS) was 56 months. Higher hemoglobin levels improved OS (HR=0.59, p=0.02), while higher adjusted ZRSR2 VAF worsened OS (HR=1.05, p=0.017). Patients with TET2 as isolated co-mutations showed better mOS than the rest of the cohort (not reached vs 41 months, p= 0.03). ZRSR2m CCUS patients showed a trend suggestive of better mOS than ZRSR2m with MNs including AML (56 vs 30 months, p=0.14), and with excluding AML (56 vs 39 months, p=0.24). On multivariate analysis, both Hgb (HR=0.61, p=0.03) and isolated TET2 co-mutation (HR=0.19, p=0.04) retained statistical significance. mOS was not affected by prior history of treatment, number of co-mutations, isolated ZRSR2, ASXL1 co-mutation, or MDS progression. Conclusion: ZRSR2m CCUS cohort was exclusively males. There was a significant number of patients with concurrent hematological malignancy or a history of prior chemo- and/or immuno-therapy (36%). Most patients had high-risk CCUS but showed a low rate of progression to MNs, especially in those with isolated ZRSR2. Additionally, patients with isolated TET2 co-mutation had better survival, indicating that TET2 confers a favorable prognosis among ZRSR2m CCUS patients.
Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
Ansell, Stephen M. , Scott, David W. , Mehta–Shah, Neha , Amengual, Jennifer E. , Cole, Peter D. , Forlenza, Christopher J. , Jegede, Opeyemi A. , Steidl, Christian , Natkunam, Yasodha , Kahl, Brad S. , Diefenbach, Catherine

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4427-4427

10.1182/blood-2024-201624 Get It

Background: The Phase 1/2 ECOG-ACRIN sponsored intergroup trial E4412 (NCT01896999) investigated brentuximab vedotin (BV) combined with the checkpoint inhibitors nivolumab (N) and ipilimumab (I) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R HL). Here we present the safety and efficacy results for the cohort of pediatric patients aged 12-17 years. Methods: Patients were randomly assigned to treatment with the doublet of BV/N or triplet of BV/N/I, with the following dosing: BV 1.8mg/kg every 21 days for up to 16 cycles; Nivolumab 3mg/mg every 21 days for up to 34 cycles; Ipilimumab 1mg/kg every 9 weeks for up to 9 doses. Response evaluation by PET/CT was performed after 4 cycles. Transplant-eligible patients with CR could discontinue protocol therapy to receive a consolidative autologous stem cell transplant (ASCT). Results: Sixteen pediatric patients with a median age of 16 (range 12-17) were randomized. 75% of patients had received only 1 prior line of treatment with none having previously received BV and only 1 patient with prior ASCT. All patients were treated (8 in each arm) and included in the pediatric safety analysis cohort receiving at least one cycle of therapy. There were four reported grade (gr) 3 or greater toxicities: lymphopenia (gr 3) and neutropenia (gr 3) on the BV/N arm; and neutropenia (gr 4) and rash (gr 3) on the BV/N/I arm. Rash of any grade was more common in patients treated with BV/N/I (n=6) compared to BV/N (n=1). Peripheral sensory neuropathy was reported in 2 patients (BV/N, gr 2, n=2) There were no grade 5 toxicities. Fourteen patients (7 in each arm) were evaluable for response. The CR rate on both the BV/N and BV/N/I arms was 100%. The median survival follow up was 23.7 months (15.7 - 31.7). The 24-month PFS was 57% for BV/N and 100% for BV/N/I. Six patients (2 BV/N; 4 BV/N/I) discontinued protocol therapy to receive a consolidative ASCT. The 24-month PFS for patients consolidated with an ASCT was 100%, with all events occurring in patients randomized to BV/N, but not receiving an ASCT. Conclusion: Pediatric patients receiving both BV/N and BV/N/I had 100% CR rate with limited toxicity. Although this is a small cohort, there have been no progression events observed in patients treated with BV/N/I, including 3 patients treated without a consolidative ASCT.
TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
Hung, Kevin, Al‐Kali, Aref , Patnaik, Mrinal M. , Price, Zoe, Kourelis, Taxiarchis , Anani, Hossein, Tefferi, Ayalew , Hung, Kevin , Hung, Kevin , Hung, Kevin, Toop, Carla , THOMAS, DANIEL W. , Gertz, Morie A. , Gonsalves, Wilson I. , Kok, Chung Hoow , Hiwase, Devendra , Shah, Meera

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4594-4594

10.1182/blood-2024-211931 Get It

Background: TP53 mutations (TP53mut) are highly prevalent in therapy-related myeloid neoplasms (t-MN) compared to de novo MN (35-40% vs 7-13%) and are associated with a poor outcome. Understanding the risk factors involved in the pathogenesis of TP53mut t-MN is critical to prevent its development. Methods: We characterized t-MN cases by examining primary cancer type vs autoimmune disease diagnosis vs solid organ transplantation, treatment modality, and latency (interval between primary cancer/disease and t-MN diagnosis) to identify patient and disease-related factors associated with TP53mut t-MN. Allelic loss of TP53mut MN was defined according to International Consensus Classification (ICC) criteria (Arber et al., Blood 2022). Results: Of 587 t-MN patients, 33% (n=194) had acute myeloid leukemia (t-AML) and 67% (n=393) had myelodysplastic syndrome (t-MDS, blasts<20%). Primary diagnosis comprised of 243 (41.6%) solid cancers and 300 (51.4%) hematological malignancies, while 7% (n=41) of t-MN cases had autoimmune disease or underwent solid organ transplant. Overall, 94 (16.1%) patients received prior radiotherapy (RT) alone and 75.6% (n=444) received chemotherapy (CT) with/without RT. 109 patients (18.7%) underwent autologous stem cell transplant (ASCT). The median latency from primary diagnosis to t-MN was 83.2 months (IQR 41.3, 153.2), and there was a trend towards shorter latency in t-AML compared to t-MDS (70.5 vs 85.8 months; P=0.07). Of the t-MN patients, 280 (47.7%) harbored TP53mut, which was associated with significantly poorer survival compared to wild-type (TP53wt) t-MN (9.7 vs 21.9 months; P <0.001). In contrast to TP53wt (59.0% vs 41.0%), the majority of TP53mut t-MN presented with t-MDS vs t-AML (75.7% vs 24.3%; P <0.001). According to ICC criteria, multi-hit MDS (n=131; 47.8%) was the most common entity, followed by AML (n=68; 24.8%), MDS/AML (n=34; 12.4%), and single-hit MDS (n=8, 2.9%). Poor prognostic karyotype changes e.g., del 5q, del 7q, complex karyotype and monosomal karyotype, were more prevalent in TP53mut compared to TP53wt t-MN. Co-mutations in other genes were enriched in TP53wt t-MN. As TP53mut t-MN is associated with a dismal outcome, we assessed the factors associated with its development. There were no significant differences in median age at primary cancer/disease diagnosis (59.0 vs 59.9 years; P=0.4) or gender (females 43.3% vs 39.3%; P=0.3) between TP53mut and TP53wt t-MN. However, TP53mut patients were older at t-MN diagnosis (69 vs 67.4 years; P=0.05). Correlations between gene mutations and prior malignancies revealed a significant association between TP53mut and hematological primary cancers (odds ratio [OR] 1.6; P=0.006), especially multiple myeloma (MM, OR 4.9; P<0.001) and lymphoproliferative disease (LPD, OR 2.0; P=0.013). Among solid cancers, head and neck malignancies were significantly associated with increased risk of developing TP53mut t-MN (OR 7.7; P=0.01). Compared to RT alone, ASCT (OR 2.2; P=0.004) and CT (OR 2.0; P=0.008) were associated with an increased risk of TP53mut t-MN. Recent studies indicate that CT/RT confer a selective advantage to preexisting TP53mut hematopoietic stem and progenitor cells, allowing clonal expansion/evolution and progression to t-MN. We hypothesized that TP53mut t-MN with high-risk disease features is a function of TP53mut clonal expansion/evolution rate and would predict latency between primary cancer and t-MN. Indeed, the latency between primary cancer and t-MN diagnosis was longer in TP53mut (87.8 months, IQR 45.5, 154.1) compared to TP53wt (74.7 months, IQR 37.5, 146.9 months) t-MN (P=0.05). Interestingly, 54% and 29% of TP53mut t-MN had a latency of ≥5 and ≥10 years, respectively. There were no correlations between latency and TP53 variant allele frequency (VAF) (r=0.38 and P=0.7) or between TP53mut t-MDS and t-AML (85.2 vs 109.3 months; P=0.9). Together, latency between primary cancer and t-MN was not associated with TP53mut t-MN phenotype, VAF or other poor-risk disease features. Conclusion: Hematological malignancies, especially MM and LPD treated with high-dose CT, were strongly associated with TP53mut t-MN development, highlighting the importance of careful and ongoing screening in this population. Also, the long latency of TP53mut t-MN provides an opportunity to devise effective surveillance strategies and preventative interventions long before TP53mut t-MN development.
Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)
Alencar, Alvaro J. , Mehta-Shah, Neha, Lu‐Emerson, Christine , Rutherford, Sarah C. , Dockter, Travis , Geyer, Susan M. , Fuente, Macarena de la, Dinner, Shira, Rubenstein, James L. , Leonard, John P. , Bobek, Olivia , Mehta–Shah, Neha , Epperla, Narendranath , Olszewski, Adam J. , Ollila, Thomas A , Singer, Samuel , Rosenstein, Lori J. , Hsi, Eric D. , Bartlett, Nancy L.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4502.4-4502.4

10.1182/blood-2024-209238 Get It

Background: The rising incidence of PCNSL in the elderly represents an unmet need with an undefined standard approach [Villano Br J Cancer 2011]. High-dose methotrexate-based (HD-MTX) therapy is feasible and effective in older patients, but outcomes in this population remain poor. Despite high response rates to HD-MTX induction therapy, poor candidacy for intensive consolidative therapy results in transient disease control that may benefit from maintenance strategies [David Am J Hematol 2023]. Lenalidomide (len) has demonstrated activity in PCNSL even at low doses and represents a potential alternative to consolidation considering its extensive use in maintenance settings [Vu Br J Haematol 2019]. Anecdotal activity in PCNSL by checkpoint inhibitors such as nivolumab (nivo) has been reported [Nayak Blood 2017], and its immune response may be enhanced by len [Görgün Clin Cancer Res 2015]. A051901 evaluates the feasibility of the addition of len and nivo to rituximab (R) and HD-MTX as first line induction therapy followed by len-nivo maintenance in elderly patients with PCNSL not eligible for intensive consolidation. Study Design and Methods: This is a single-arm phase 1 multicenter US study (NCT04609046) conducted by the Alliance for Clinical Trials in Oncology with a traditional 3+3 design. Eligible patients are 18 years of age or older with untreated diffuse large B-cell lymphoma PCNSL diagnosed through brain biopsy or resection, or cerebrospinal (CSF) or vitreous fluid not considered candidates for high dose chemotherapy consolidation. This study is available to all eligible patients, regardless of race, gender, or ethnic origin. Patients must have adequate end-organ function including creatinine clearance of at least 50 mL/min. Use of systemic corticosteroids for disease control to be tapered after initiation of therapy is allowed. Induction consists of six 14-day cycles with rituximab 500 mg/m2 i.v. on day 1, HD-MTX 3g/m2 i.v. on day 2. In the most recent treatment schedule, a 5-day course of lenalidomide PO at different dose levels (dose level (DL) 1 = 10 mg, DL2 = 15 mg, DL3 = 20 mg) is initiated immediately after adequate clearance of HD-MTX. Once a maximum tolerated dose (MTD) of len is defined, a subsequent cohort will evaluate the addition of nivo 240 mg i.v. to the day 14 of the induction cycle of R-HD-MTX plus len at the MTD. Patients who present any clinical benefit from induction with at least stable disease by International PCNSL Collaborative Group response criteria are eligible for maintenance - twelve 28-day cycles of therapy with len 15 mg PO from day 1 to day 21 (regardless of dose during induction) +/- nivo 480 mg i.v. on day 1 (for those who received len and nivo during induction). The primary endpoint of the induction therapy is the MTD of len when given in combination with R-HD-MTX; the primary endpoint of maintenance is its feasibility, defined as the proportion of patients able to remain on maintenance for at least 6 cycles. As of July 2024, 16 patients have been enrolled with a maximum expected sample size of 47 patients with the assumption of 75% of patients being eligible to proceed with maintenance and 50% of those who begin maintenance not progressing in the first 6 cycles. Overall response, adverse events, progression-free and overall survival will be evaluated in all eligible patients with a focus on the outcome of patients treated at the MTD. For patients who consent to biobanking, diagnostic tissue, peripheral blood and CSF from different timepoints are collected and banked with planned exploratory analyses including whole exome sequencing, circulating tumor DNA, proteomics, metabolomics. Support: U10CA180821, U10CA180882. https://acknowledgments.alliancefound.org.
Clinical Characteristics and Prognostic Significance of Co-Mutated SETBP1/GATA2 Myeloid Neoplasms
Jabban, Yazan, He, Rong , Bessonen, Kurt, Foran, James M. , Yi, Cecilia Y. Arana , Matin, Aasiya , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Al‐Kali, Aref , Greipp, Patricia T. , Jevremović, Dragan , Yi, Cecilia Arana , Saliba, Antoine N. , Hefazi, Mehrdad , Hogan, William J. , Shah, Meera , Alkhateeb, Hassan B.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 6700-6700

10.1182/blood-2024-201128 Get It

Background: SETBP1 gene, located on 18q12.3, is a major oncogene in myeloid neoplasms. GATA2 gene, located on 3q21, is one of the six GATA transcription factors regulating gene expression via two conserved zinc finger domains (ZF). Previous data suggested that in patients with germline GATA2 mutation (m), acquisition of a somatic SETBP1 mutation (m) was associated with leukemic transformation among patients with excess blast MDS and CMML. Aim: To study the characteristics of patients with somatic SETBP1-GATA2 mutated myeloid neoplasms. Methods: This study is a retrospective study at Mayo Clinic. After obtaining IRB approval, we retrospectively reviewed the charts of patients who had myeloid NGS panel results between 2016-2023. All data were recorded at time of first NGS. Cohort 1 was defined as patients with SETBP1m and GATA2m, cohort 2; patients with SETBP1m and GATA2wt, and cohort 3; patients with SETBP1wt and GATA2m. Germline work-up was not performed in the majority of GATA2 cases. We stratified risk based on the European LeukemiaNet 2022 guidelines for AML, IPSS-M for MDS and MDS/MPN, and CPSS-M for CMML. Overall survival (OS) was calculated from date of NGS to date of last follow-up based on Kaplan-Meier estimates and Cox regression analysis. For statistical analysis, we used BlueSky Statistics V10.3.1. Results: General characteristics: 114 patients had SETBP1m (median VAF= 39%), and 63 patients had GATA2m (median VAF= 35%). Nine patients had co-occurring SETBP1m/GATA2m mutations (cohort 1). 4/9 patients in cohort 1 had MDS/MPN (44.4%), while only 13/105 in cohort 2 (12.4%) had MDS/MPN (P=0.02). AML was seen in 2 patients in cohort 1 (22.2%) compared to18 in cohort 2 (17.1%) (p=0.6). The median WBC count was 22.9 x 109 cells/L among cohort 1 compared to 9 x 109 cells/L among cohort 2 cases (p=0.09). BM blasts were higher in cohort 3 (7%) compared to cohort 1 (5%) and cohort 2 (3%) (p=0.09), while peripheral blasts tended to be lower in cohort 2 (1%) in comparison to cohort 1 (6%) and cohort 3 (4%) (p=0.48). Genetic characteristics: In cohort 1,7 GATA2m clustered in zinc finger 2 (ZF2) (77.8%), while the other two mutations were outside the ZF domains (22.2%). This was higher than the ZF2 mutated cases in cohort 3 (46.3%, p=0.1). Abnormal cytogenetics were seen in 66.7% of cohort 1 patients and 45% of cohort 2 (p= 0.3). Two cases with trisomy 8 were seen among patients in cohort 1 (22.2%), compared to only 4.9% in cohort 2 (p=0.09). Two incidences of isochromosome 17q [i(17q)] were seen in cohort 1 (22.2%), versus 5 cases in cohort 2 (4.8%) and 1 case in cohort 3 (1.9%) (p= 0.068). Co-mutations: The median number of co-mutationswas 3 in both cohort 1 and cohort 2 (p= 0.6). In cohort 1, ASXL1 and SRSF2 mutations were the most common (7/9, 77.8%) followed by NRAS (22.2%) and TET2 (22.2%). 77.8% of cohort 1 patients had SRSF2 co-mutation, compared to 44.8% in cohort 2 (p=0.08), and 27.8% in cohort 3 (p= 0.006). No isolated SETBP1m/GATA2m cases were found. Survival: Patients in cohort 1 had a numerically higher median OS compared to those in cohort 2 (19.4 vs 15.4 months, p= 0.3). When comparing with the cohort 3, patients in cohort 1 tended to have better outcomes (median OS= 19.4 vs 13.8 months, p=0.8). Among cohort 1, SRSF2 co-mutation was associated with worse survival outcomes compared to patients with SRSF2wt (median OS= 5.3 vs 19.4 months, p= 0.02); this association was not found in cohort 2 (12.5 vs 18.4 months, p= 0.3) and cohort 3 (13.2 vs 17.1 months, p= 0.4). Allogeneic hematopoietic cell transplantation was associated with favorable survival outcomes in all cohorts (cohort 1: 22.6 vs 7.8 months, p= 0.1; cohort 2: 20.9 vs 12.5 months, p= 0.04; cohort 3: 25.6 vs 13.1 months, p= 0.03). Conclusion: SETBP1m/GATA2m myeloid neoplasms included a significantly higher proportion of MDS/MPN overlap cases in comparison with the SETBP1m/GATA2wt group. The SETBP1m/GATA2m group had a higher proportion of ZF2 GATA2m and SRSF2 co-mutation compared to patients with SETBP1wt/GATA2m. Survival of SETBP1m/GATA2m patients was not worse compared to SETBP1wt/GATA2m or SETBP1m/GATA2wt.
Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy
Gupta, Supriya , Corraes, Andre De Menezes Silva , Bansal, Radhika , Khurana, Arushi , Kourelis, Taxiarchis , Abdallah, Nadine , Gertz, Morie A., Warsame, Rahma , Hayman, Suzanne R. , Kapoor, Prashant , Ansell, Stephen M., Kumar, Shaji, Sandahl, Tyler B. , Nedved, Adrienne, Barreto, Jason N. , Johnston, Patrick B. , Lin, Yi , Alkhateeb, Hassan B. , Moraes, Alice Gallo de , Vergidis, Paschalis , Kenderian, Saad S. , Durani, Urshila , Paludo, Jonas , Cook, Joselle , Bennani, N. Nora , Villasboas, José C. , Shah, Meera , Wang, Yucai , Gertz, Morie A. , Kumar, Shaji , Dingli, David , Wolf, Robert Christian , Leung, Nelson

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 7165-7165

10.1182/blood-2024-211111 Get It

Background and Methods: IEC-HS is a hyperinflammatory state with high morbidity and mortality. Effective interventions to reverse the process early in the clinical course may be critical to improve outcomes. We previously examined cytokine differences between IEC-HS and other secondary hemophagocytic lymphohistiocytosis, and found significant differences in the patterns and outcomes.(1) This study examines cytokine profiles (CP) of patients treated with CAR-T from 9/2019 to 3/2024 who developed CRS, MAS-L and IEC-HS. Demographics and lab results were compared among the three groups and correlated with outcomes. Results: CP was tested in 113 of 366 CAR-T patients: 74 with CRS, 19 with MAS-L, and 20 with IEC-HS. The racial distribution was 93% White/Caucasian, 2% Black or African American, 1% Asian, 1% Native American and 3% other or unavailable. No differences were seen in demographics between groups except a higher percentage of patients with ECOG performance status ≥2 in IEC-HS (p=0.037). Incidence of IEC-HS by disease: 3.6% (7/193) in lymphoma, 5% (8/159) myeloma and 28.5% (4/14) B-acute lymphoblastic leukemia (p=0.0002). Incidence of IEC-HS by CAR-T product: 3% (4/150) in Axi-cel, 23% (6/26) in Brexu-cel, 8% (1/13) in Tisa-cel, 5% each (3/60) in Cilta-cel and Ide-cel, and 0/17 in Liso-cel (p=0.001). Prior to lymphodepletion, labs were already different among the CRS, MAS-L, and IEC-HS groups: hemoglobin (g/dL: 11.1, 9.6, 8.45); platelets (x109/L: 168, 116, 52.5); ferritin (µg/L: 115, 946, 1944). CP was started when patients needed a second dose of tocilizumab or concern for developing MAS-L/IEC-HS, and continued daily until clinical improvement or resolution of inflammatory state. Tocilizumab and dexamethasone use were similar across groups. Other therapies used were vasopressors (3%, 10.5%, 45%; p<0.0001), Methylprednisolone (20%, 31.6%, 50%; p=0.027), Anakinra (12%, 63%, 85%; p<0.0001), Siltuximab (9.5%, 16%, 30%; p=0.06), Basiliximab (30% of IEC-HS), and continuous veno-venous hemofiltration (30% of IEC-HS). Among the first CP, the CRS group had lower levels of cytokines (in pg/mL) compared to MAS-L and IEC-HS groups: TNF (31, 62.9, 47.7), IL-10 (29.3, 97.7, 169), IL-18 (794, 1353, 2011), IFN-gamma (74, 281, 250), MCP-1 (689, 2722, 2485.5), MIP-1 alpha (220, 234, 247.5), IL-6 (>315: 45%, 79%, 70%), soluble IL-2R alpha (>4000: 45%, 84%, 70%). The percentage of patients who received anakinra before CP1 were 4% (CRS), 21% (MAS-L) and 25% (IEC-HS) (p=0.007). IL-1 beta was below threshold among all patients who received anakinra in CRS and MAS-L and 75% in IEC-HS, suggesting rapid and effective IL-1 suppression by anakinra except in IEC-HS. Cytokines trends 24 hours and 48 hours after the first CP differed between MAS-L and IEC-HS. MAS-L had decreased TNF (62.9, 40.4, 18.5) and MCP-1 (2722, 355, 104) while these cytokines remained elevated or increased in IEC-HS (TNF: 47.7, 105.5, 62.6; MCP-1: 2486, 2276, 1585). IL-18 was minimally elevated in MAS-L (1353, 1955, 3068) and significantly increased in IEC-HS (2011, 2420, 4048). Notably, CP2 and CP3 levels of these cytokines in IEC-HS were statistically significantly higher than corresponding CPs among CRS and MAS-L. In addition, patients who died with persistent E. faecium bacteremia had higher IL-18 on CP3. Infections occurred in 43%, 58%, and 85% respectively (p=0.002), including E. faecium bacteremia (3%, 5%, 35%; p=0.0004), CMV viremia (30% of IEC-HS patients vs. 11% of non-IEC-HS; p=0.025), and invasive fungal infections (15% of IEC-HS patients; p=0.0001). Between the IEC-HS and non-IEC-HS groups, day 100 non-relapse mortality was 35% vs. 0 (p<0.0001), day 100 all-cause mortality was 45% vs. 3% (p<0.0001), and E. faecium bacteremia-related deaths were 50% vs. 1% (p<0.0001). Conclusions: CRS, MAS-L andIEC-HS are known complications of CAR-T. Cytokine-directed therapy can modify the cytokine milieu and control the inflammatory process. However, excess immunosuppression may result in life-threatening infections. Further studies are needed to identify optimal biomarker-guided immunosuppressive strategies to control the inflammatory cascade, while avoiding excess immunosuppression. References: 1. Leung, Nelson, et al. “Outcomes of patients who received CAR T cell therapy and developed IEC-HS treated with cytokine directed therapy.” (2024): 7516-7516.
TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival
Gangat, Naseema , Elbeih, Azeem, Ghosoun, Nour, Abdelmagid, Maymona, Al‐Kali, Aref , Begna, Kebede, Elliott, Michelle A. , Litzow, Mark R. , Mangaonkar, Abhishek A. , Foran, James M. , Palmer, Jeanne , Yi, Cecilia Y. Arana , Patnaik, Mrinal M. , Pardanani, Animesh , Tefferi, Ayalew , McCullough, Kristen , Elbeih, Azeem, Ghosoun, Nour, Alkhateeb, Hassan B. , Hefazi, Mehrdad , Hogan, William J. , Saliba, Antoine N. , Shah, Meera , Badar, Talha , Yi, Cecilia Arana

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 6657-6657

10.1182/blood-2024-193917 Get It

Background Blast or accelerated phase myeloproliferative neoplasm (MPN-BP/AP) carries a dismal prognosis, with 3-year survival estimates of <5% (BCJ 2023;108). Patients with MPN-BP/AP were excluded from venetoclax (Ven) plus hypomethylating agent (HMA) clinical trials for acute myeloid leukemia (NEJM 2020;383:617). In the current retrospective study, we examined response patterns and long-term survival of newly-diagnosed MPN-BP/AP patients who received treatment with Ven+HMA, outside of clinical trials. Methods Newly-diagnosed patients with MPN-BP/AP treated with Ven+HMA at the Mayo Clinic, between March 2019 and May 2024, were retrospectively reviewed. Diagnostic criteria were according to the International Consensus Classification (Blood 2022;140:1200). Cytogenetic and molecular studies were performed by conventional karyotype and next-generation sequencing, respectively. All patients received at least one cycle of Ven+HMA (azacitidine 75 mg/m2 days 1-7 or decitabine 20 mg/m2 days 1-5). Response was assessed according to the 2022 European Leukemia Net criteria (Blood 2022;140:1345). Standard statistical analyses were performed using JMP Pro (Version 17.1.0). Results Patient characteristics 70 patients (median age 73 years, 59% males, 48% splenomegaly >14 cm, 4% isolated myeloid sarcoma) with newly-diagnosed MPN-BP (n=58) or AP (n=12) received Ven+HMA with (n=13) or without (n=57) concomitant JAK2 inhibitor. Driver mutation distribution was 69% JAK2, 21% CALR, 6% MPL, and 4% triple negative. Mutations involved ASXL1 (31%), TP53 (28%), TET2 (28%), RUNX1 (25%), SRSF2 (18%), IDH2 (12%), U2AF1 (11%), DNMT3A (9%), IDH1 (7%), and K/NRAS (7%). Karyotype was abnormal in 50 (76%) of 66 informative cases, of which 28 (56%) were complex (CK). Median TP53 mutation variant allele frequency (VAF) was 30% (8-96%) and all evaluable cases displayed CK (n=18). Response and Survival Complete remission (CR; 21%) or CR with incomplete count recovery (CRi; 19%) was documented in 28 (40%) patients with residual MPN in 18 (64%) patients. Median response duration was 5.5 months (1-60 months). After a median follow up of 7 months (1-62 months), 48 (69%) deaths, 13 relapses (46%), and 15 (21%) allogeneic stem cell transplants (ASCT; 12 in CR/CRi) were recorded. Median overall survival (OS) was 9 months and was superior with ASCT (median 22 vs. 8 months; p=0.01). In univariate analysis, transplant-censored survival was superior with CR/CRi (12 vs. 5 months; p<0.01) and IDH1 mutation (33 vs. 8 months; p=0.04) and inferior with CK (7 vs. 10 months; p=0.05), TP53 mutation (5 vs. 10 months; p<0.01), post polycythemia vera myelofibrosis (post-PV MF) (3 vs. 9 months; p=0.01), and splenomegaly >14 cm (5 vs. 16 months; p<0.01). Multivariable analysis confirmed the negative survival impact of not achieving CR/CRi (HR 3.8; p<0.01) and presence of TP53 mutation (HR 4.0; p<0.01); median survival (1/3-year survival rate) was 3 months (10%/0%) in TP53 mutated patients not achieving CR/CRi (n=11) vs. 27 months (65%/28%) in TP53 unmutated cases achieving CR/CRi (n=19) (p < 0.01). Median survival in patients with TP53 mutations or CK who achieved CR/CRi (n=7; 7 months) was inferior to that in treatment responders without TP53 mutations or CK (n=18; 23 months; p=0.01). CR/CRi rates in the presence vs. absence of TP53 mutations were 42% vs. 39% (p=0.80) and of CK (25% vs. 50% (p=0.04). Importantly, responses in the presence of TP53 mutations or CK were too short-lived to allow successful bridging to ASCT (median 2 vs. 9 months; p<0.01). Additional predictors of inferior treatment response included splenomegaly >14 cm (24% vs. 53%; p=0.01), and post-PV MF (0% vs. 46%; p<0.01) while SRSF2 (67% vs. 34%; p=0.04) and IDH2 mutations (75% vs. 35%; p=0.03) were associated with favorable response. In multivariable analysis, CK (p=0.04) and splenomegaly >14 cm (p=0.01) remained independent predictors of inferior response. The use of concomitant JAK2 inhibitor therapy did not impact treatment response (CR/CRi 46% vs. 39%; p=0.62) or survival (median 9 vs. 8 months; p=0.71). Conclusions TP53 mutations and CK undermine the value of Ven+HMA, with or without concomitant JAK2 inhibitor, in enabling successful bridging of newly-diagnosed MPN-BP/AP to ASCT. An alternative treatment approach is advised, in the particular scenario, while the observed 3-year survival rate of 28%, in treatment responders without TP53 mutations, is encouraging.